sell on fact or a re-rate on news? , page-7

Thanks, however maybe I should rephrase my question:

If trials are successful, enough to warrant a "next step". Is the general consensus here that the sp will rise as confidence of future revenue grows. Or is the consensus that the sp will drift back down while shareholders and ANP wait for and/or FPO for the cash to facilitate the "next step" in their business plan.

Like I said anyones experienced view would be well appreciated. And, I am DMOR.. in fact It would be great if anyone can point me to some Aussie bio techs in the past who have gone from researcher to licensor.

Thanks! I'm sure there are a few others out there with the same question?